Cumberland Pharmaceuticals (CPIX) Revenue & Revenue Breakdown
Cumberland Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$39.55M
Latest Revenue (Q)
$9.85M
Main Segment (Y)
Product
Main Geography (Y)
Non-US
Cumberland Pharmaceuticals Revenue by Period
Cumberland Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $39.55M | -5.85% |
| 2022-12-31 | $42.01M | 16.75% |
| 2021-12-31 | $35.99M | -3.89% |
| 2020-12-31 | $37.44M | 8.88% |
| 2019-12-31 | $34.39M | -15.59% |
| 2018-12-31 | $40.74M | -0.99% |
| 2017-12-31 | $41.15M | 24.60% |
| 2016-12-31 | $33.03M | -1.47% |
| 2015-12-31 | $33.52M | -9.17% |
| 2014-12-31 | $36.90M | 15.22% |
| 2013-12-31 | $32.03M | -34.44% |
| 2012-12-31 | $48.85M | -4.48% |
| 2011-12-31 | $51.14M | 11.48% |
| 2010-12-31 | $45.88M | 5.37% |
| 2009-12-31 | $43.54M | 24.13% |
| 2008-12-31 | $35.08M | 24.98% |
| 2007-12-31 | $28.06M | 57.52% |
| 2006-12-31 | $17.82M | 66.66% |
| 2005-12-31 | $10.69M | - |
Cumberland Pharmaceuticals generated $39.55M in revenue during NA 2023, up -5.85% compared to the previous quarter, and up 97.08% compared to the same period a year ago.
Cumberland Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $9.85M | 15.90% |
| 2024-03-31 | $8.50M | -9.15% |
| 2023-12-31 | $9.35M | -7.27% |
| 2023-09-30 | $10.09M | -7.37% |
| 2023-06-30 | $10.89M | 18.04% |
| 2023-03-31 | $9.22M | 1.11% |
| 2022-12-31 | $9.12M | -20.06% |
| 2022-09-30 | $11.41M | 10.82% |
| 2022-06-30 | $10.30M | -7.84% |
| 2022-03-31 | $11.18M | 34.32% |
| 2021-12-31 | $8.32M | 3.06% |
| 2021-09-30 | $8.07M | -10.85% |
| 2021-06-30 | $9.06M | -14.06% |
| 2021-03-31 | $10.54M | 2.69% |
| 2020-12-31 | $10.26M | 10.93% |
| 2020-09-30 | $9.25M | -3.62% |
| 2020-06-30 | $9.60M | 15.21% |
| 2020-03-31 | $8.33M | -39.10% |
| 2019-12-31 | $13.68M | 31.88% |
| 2019-09-30 | $10.37M | -10.44% |
| 2019-06-30 | $11.58M | -2.71% |
| 2019-03-31 | $11.90M | -11.82% |
| 2018-12-31 | $13.50M | 58.94% |
| 2018-09-30 | $8.49M | -16.44% |
| 2018-06-30 | $10.16M | 18.35% |
| 2018-03-31 | $8.59M | -26.28% |
| 2017-12-31 | $11.65M | 4.04% |
| 2017-09-30 | $11.20M | 29.19% |
| 2017-06-30 | $8.67M | -10.06% |
| 2017-03-31 | $9.64M | 6.11% |
| 2016-12-31 | $9.08M | 3.29% |
| 2016-09-30 | $8.79M | 18.57% |
| 2016-06-30 | $7.41M | -4.17% |
| 2016-03-31 | $7.74M | -3.73% |
| 2015-12-31 | $8.04M | 1.93% |
| 2015-09-30 | $7.89M | -11.50% |
| 2015-06-30 | $8.91M | 2.57% |
| 2015-03-31 | $8.69M | -6.89% |
| 2014-12-31 | $9.33M | -4.11% |
| 2014-09-30 | $9.73M | -0.22% |
| 2014-06-30 | $9.75M | 20.47% |
| 2014-03-31 | $8.09M | -0.81% |
| 2013-12-31 | $8.16M | 24.98% |
| 2013-09-30 | $6.53M | -7.80% |
| 2013-06-30 | $7.08M | -30.97% |
| 2013-03-31 | $10.26M | -25.10% |
| 2012-12-31 | $13.70M | 9.29% |
| 2012-09-30 | $12.53M | 1.33% |
| 2012-06-30 | $12.37M | 20.58% |
| 2012-03-31 | $10.26M | -21.30% |
| 2011-12-31 | $13.03M | -0.17% |
| 2011-09-30 | $13.05M | -9.28% |
| 2011-06-30 | $14.39M | 34.90% |
| 2011-03-31 | $10.67M | -16.76% |
| 2010-12-31 | $12.81M | 5.12% |
| 2010-09-30 | $12.19M | 13.51% |
| 2010-06-30 | $10.74M | 6.01% |
| 2010-03-31 | $10.13M | -5.45% |
| 2009-12-31 | $10.71M | -21.21% |
| 2009-09-30 | $13.60M | 38.46% |
| 2009-06-30 | $9.82M | 4.42% |
| 2009-03-31 | $9.40M | -4.14% |
| 2008-12-31 | $9.81M | 14.05% |
| 2008-09-30 | $8.60M | 2.93% |
| 2008-06-30 | $8.36M | 0.65% |
| 2008-03-31 | $8.30M | 11.70% |
| 2007-12-31 | $7.43M | - |
Cumberland Pharmaceuticals generated $9.85M in revenue during Q2 2024, up 15.90% compared to the previous quarter, and up 106.77% compared to the same period a year ago.
Cumberland Pharmaceuticals Revenue Breakdown
Cumberland Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $37.51M | - | - | - | - |
| Manufactured Product, Other | $2.04M | - | - | - | - |
| Kristalose | - | $15.21M | $15.99M | $15.57M | $12.90M |
| Product, Vibativ | - | $7.49M | $11.70M | $10.87M | $8.69M |
| Caldolor | - | $4.83M | $4.97M | $5.34M | $5.22M |
| Acetadote | - | $501.04K | $850.99K | $1.87M | $3.82M |
| Vaprisol | - | $-447.70K | $1.86M | $1.08M | $936.62K |
| Sancuso | - | $13.21M | - | - | - |
| RediTrex | - | $-126.73K | $55.32K | $856.66K | - |
| Omeclamox-Pak | - | - | $-388.66K | $257.09K | $837.83K |
| Product, Ethyol | - | - | - | - | $12.77M |
| Product, Totect | - | - | - | - | $369.91K |
Cumberland Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (94.84%), and Manufactured Product, Other (5.16%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product - Other | $275.33K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product - Vibativ | $1.61M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| VIBATIV | - | $2.79M | $2.15M | $1.85M | $1.91M | $1.60M | $2.50M | $325.77K | $399.95K | $1.13M | $2.81M | $3.30M | $2.43M | $1.45M | $2.60M | $2.06M | - | - | - | - |
| Acetadote | - | $120.05K | $150.16K | $169.86K | $163.35K | $99.79K | $126.79K | $111.09K | $212.29K | $4.01M | $5.28M | $2.99M | $347.03K | $218.46K | $595.31K | $713.90K | $1.22M | $777.18K | $983.47K | $849.50K |
| Sancuso | - | $1.93M | $1.92M | $1.89M | $2.45M | $3.96M | $3.40M | $3.40M | - | - | - | - | - | - | - | - | - | - | - | - |
| RediTrex | - | $-122.56K | $9.49K | $-141.04K | $-365.44K | $85.81K | $93.68K | $59.23K | $68.61K | $11.46K | $7.38K | $-32.25K | - | - | - | - | - | - | - | - |
| Other Products | - | $299.36K | $1.30M | $197.19K | $496.79K | $480.16K | $295.62K | $178.89K | $461.15K | $182.10K | $265.05K | $874.21K | $459.56K | $270.85K | $612.03K | $709.22K | - | - | - | - |
| Omeclamox-Pak | - | $23.29K | $8.06K | $-2.52K | $35.60K | $-26.41K | $22.74K | $63.03K | $1.90M | $1.84M | $5.05M | $-383.35K | $516.07K | $10.95K | $114.77K | $43.62K | $116.06K | $478.60K | $199.54K | - |
| Kristalose | - | $3.89M | $4.11M | $4.32M | $3.79M | $3.90M | $3.57M | $3.95M | $3.71M | $1.26M | $938.33K | $1.54M | $5.18M | $3.62M | $3.48M | $3.31M | $3.17M | $2.92M | $3.48M | $3.31M |
| Caldolor | - | $1.16M | $1.23M | $935.04K | $1.75M | $921.81K | $1.19M | $959.63K | $1.24M | $22.69K | $-24.11K | $-450.26K | $1.66M | $1.42M | $1.17M | $1.10M | $1.68M | $1.17M | $1.05M | $1.32M |
| Vaprisol | - | - | $23.86K | $16.01K | $-195.64K | $-436.00 | $-134.62K | $-117.00K | $-1.55K | $368.73K | $152.78K | $117.19K | $286.41K | $406.16K | $174.16K | $208.76K | $212.47K | $224.94K | $212.53K | $286.68K |
| Grant | - | - | - | - | - | - | - | $40.00K | $20.00K | $200.00K | $100.00K | $100.00K | $100.00K | - | - | - | - | - | - | - |
| Totect | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $137.34K | $154.91K | $80.90K |
| Ethyol | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.30M | $2.01M | $3.09M |
Cumberland Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product - Vibativ (85.36%), and Product - Other (14.64%).
Cumberland Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Non-US | $1.10M | $1.50M | $2.20M | $2.40M | $1.50M |
Cumberland Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 23: Non-US (100.00%).
Cumberland Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTPI | Petros Pharmaceuticals | $5.82B | $1.39M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| ORGO | Organogenesis | $433.14M | $130.23M |
| PROC | Procaps Group | $409.92M | $118.41M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| KMDA | Kamada | $144.76M | $37.40M |
| LFCR | Lifecore Biomedical | $103.27M | $35.70M |
| ALIM | Alimera Sciences | $80.75M | $23.01M |
| CPIX | Cumberland Pharmaceuticals | $39.55M | $9.85M |
| BFRI | Biofrontera | $34.01M | $7.83M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| EVOK | Evoke Pharma | $5.18M | $1.74M |
| AKAN | Akanda | $2.16M | $762.61K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
| IXHL | Incannex Healthcare | - | - |
| PRFX | PainReform | - | - |
| RGC | Regencell Bioscience | - | - |
CPIX Revenue FAQ
What is Cumberland Pharmaceuticals’s yearly revenue?
Cumberland Pharmaceuticals's yearly revenue for 2023 was $39.55M, representing a decrease of -5.85% compared to 2022. The company's yearly revenue for 2022 was $42.01M, representing an increase of 16.75% compared to 2021. CPIX's yearly revenue for 2021 was $35.99M, representing a decrease of -3.89% compared to 2020.
What is Cumberland Pharmaceuticals’s quarterly revenue?
Cumberland Pharmaceuticals's quarterly revenue for Q2 2024 was $9.85M, a 15.90% increase from the previous quarter (Q1 2024), and a -9.55% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $8.5M, a -9.15% decrease from the previous quarter (Q4 2023), and a -7.88% decrease year-over-year (Q1 2023). CPIX's quarterly revenue for Q4 2023 was $9.35M, a -7.27% decrease from the previous quarter (Q3 2023), and a 2.51% increase year-over-year (Q4 2022).
What is Cumberland Pharmaceuticals’s revenue growth rate?
Cumberland Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 9.91%, and for the last 5 years (2019-2023) was 15.02%.
What are Cumberland Pharmaceuticals’s revenue streams?
Cumberland Pharmaceuticals's revenue streams in c 23 are Product, and Manufactured Product, Other. Product generated $37.51M in revenue, accounting 94.84% of the company's total revenue Manufactured Product, Other generated $2.04M in revenue, accounting 5.16% of the company's total revenue
What is Cumberland Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Cumberland Pharmaceuticals was Product. This segment made a revenue of $37.51M, representing 94.84% of the company's total revenue.